Atlas Trials

Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

Clinical trial NCT02390219 · COMPLETED

Trial details

NCT number
NCT02390219
Sponsor
Vertex Pharmaceuticals Incorporated
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Cystic FibrosisAdvanced Lung Disease
Start date
2015-03-01
Primary completion
2016-10-01
Enrollment
46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.